Wells Fargo & Company Issues Positive Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its price objective raised by Wells Fargo & Company from $88.00 to $111.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 65.08% from the company’s previous close.

A number of other research firms also recently weighed in on KROS. Guggenheim reaffirmed a “buy” rating and set a $102.00 price target (up from $96.00) on shares of Keros Therapeutics in a research note on Wednesday, December 4th. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating on the stock. Scotiabank began coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Keros Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $95.22.

Keros Therapeutics Stock Performance

KROS traded up $0.93 during trading on Wednesday, reaching $67.24. The company had a trading volume of 19,113 shares, compared to its average volume of 376,474. The firm’s 50-day simple moving average is $60.63 and its 200 day simple moving average is $52.96. The company has a market cap of $2.72 billion, a price-to-earnings ratio of -12.91 and a beta of 1.20. Keros Therapeutics has a 12-month low of $27.31 and a 12-month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million for the quarter. During the same quarter in the previous year, the firm earned ($1.33) earnings per share. The business’s quarterly revenue was up 4750.0% compared to the same quarter last year. On average, sell-side analysts expect that Keros Therapeutics will post -5.26 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC increased its stake in shares of Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares during the period. Alkeon Capital Management LLC increased its position in Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after buying an additional 298,694 shares during the period. Darwin Global Management Ltd. lifted its holdings in shares of Keros Therapeutics by 6.3% during the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock worth $68,772,000 after buying an additional 89,952 shares during the last quarter. Point72 Asset Management L.P. boosted its position in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after acquiring an additional 577,220 shares during the period. Finally, Holocene Advisors LP grew its stake in shares of Keros Therapeutics by 22.5% in the third quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after acquiring an additional 154,784 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.